Taro Pharmaceutical Industries Ltd.
283 articles about Taro Pharmaceutical Industries Ltd.
-
Taro to Announce Full Year Results on May 26, 2022
5/21/2022
Taro Pharmaceutical Industries Ltd. announced that it plans to release its financial results for the year ended March 31, 2022, after the close of market on Thursday, May 26, 2022.
-
Taro Completes Acquisition of Alchemee
2/28/2022
Taro Pharmaceutical Industries Ltd. announced the completion of its acquisition of Alchemee, formerly The Proactiv Company, from Galderma.
-
Taro Provides Results for December 31, 2021
1/27/2022
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2021.
-
Taro to Announce Third Quarter Results on January 27, 2022
1/21/2022
Taro Pharmaceutical Industries Ltd. announced that it plans to release its financial results for the quarter and nine months ended December 31, 2021, after the close of market on Thursday, January 27, 2022.
-
Taro Provides Results for September 30, 2021
10/28/2021
Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and six months ended September 30, 2021.
-
Taro Provides Results for Quarter Ended June 30, 2021
7/28/2021
Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter ended June 30, 2021.
-
Taro Announces Resignation of Chief Financial Officer
7/14/2021
Taro Pharmaceutical Industries Ltd. announced that it has accepted the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021.
-
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2021
6/18/2021
Taro Pharmaceutical Industries Ltd. announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2021, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section of Taro’s website at www.taro.com .
-
Taro Provides Results for the Year Ended March 31, 2021
5/19/2021
Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and year ended March 31, 2021.
-
Taro to Announce Full Year Results on May 19, 2021
5/12/2021
Taro Pharmaceutical Industries Ltd. announced that it plans to release its financial results for year ended March 31, 2021, on Wednesday, May 19, 2021.
-
Taro Provides Results for December 31, 2020
1/27/2021
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2020. Quarter ended December 31, 2020 Highlights ─ compared to December 31, 2019 Net sales of $140.1 million decreased $7.5 million.
-
Taro to Announce Second Quarter Results on October 28, 2020
10/21/2020
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2020, on Wednesday, October 28, 2020. The Company will conduct an earnings call at 8:00 am ET on Thursday, October 29, 2020, where senior management will discuss the Company’s performance and ans
-
Taro Provides Results for Quarter Ended June 30, 2020
7/29/2020
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) today provided unaudited financial results for the quarter ended June 30, 2020.
-
Crescita to Receive One-time Cash Payment Following Amendment to Pliaglis® U.S. Licensing Agreement
7/28/2020
Crescita Therapeutics Inc. announced that it has entered into an amendment to the development and commercialization agreement with Taro Pharmaceuticals Inc. with regard to Pliaglis® in the United States.
-
Taro to Announce First Quarter Results on July 29, 2020
7/22/2020
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2020, after the close of market on Wednesday, July 29, 2020.
-
Taro Annual Report on Form 20-F Available for Fiscal Year Ended March 31, 2020
6/19/2020
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company") announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2020, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section of Taro’s website at www.taro.com . Hard copies of the report may be ordered free of charge by sending requests to: Taro Pharmaceuticals
-
NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical Industries, for Its Fixed Combination of an Ophthalmic Quinolone Antibiotic With an Anti-inflammatory Steroid
6/17/2020
NTC Srl, an R&D focused pharmaceutical company headquartered in Italy, has granted exclusive license and distribution rights to one of its research and development products, a fixed combination in eye drops, in Israel to Taro Pharmaceutical Industries, a research-based international pharmaceutical company.
-
Taro to Announce Full Year Results on May 19, 2020
5/13/2020
Taro Pharmaceutical Industries Ltd. announced that it plans to release its financial results for year ended March 31, 2020, on Tuesday, May 19, 2020.
-
Taro Appoints New Chief Financial Officer - April 6, 2020
4/6/2020
Taro Pharmaceutical Industries Ltd. announced the appointment of Daphne Huang as Vice President, CFO and Chief Accounting Officer
-
Taro Pharmaceuticals U.S.A. Issues Voluntary Nationwide Recall of Phenytoin Oral Suspension USP, 125 mg/5 mL Due to Possible Underdosing or Overdosing
2/20/2020
Feb. 20, 2020 22:54 UTC HAWTHORNE, N.Y.--( BUSINESS WIRE )-- Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”) is voluntarily recalling two (2) lots of Phenytoin Oral Suspension USP, 125 mg/5 mL both in 237 mL bottles, to the consumer level. Phenytoin Oral Suspension USP, 125 mg/5 mL is indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and is packaged in amber plastic bottles with an inner seal and a white child proof closur